Sofosbuvir, simeprevir, and ribavirin for the treatment of hepatitis C virus recurrence in human immunodeficiency virus/hepatitis C virus–coinfected liver transplant recipients

TO THE EDITORS: For human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus (HCV), poor graft survival after liver transplantation (LT) has prompted concerns about their suitability for LT.1 The availability of oral direct-acting antiviral drugs for HCV offers new opportunities for managing HCV disease in LT recipients with HCV and HIV and potentially improving long-term survival,2 as shown by the 2 patients reported here.

[1]  D. Stablein,et al.  Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  N. Terrault,et al.  Advances in therapy for HIV/hepatitis C virus-coinfected patients in the liver transplant setting. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.